Evaluation of Safety and Effectiveness of TLD Radiofrequency Ablation in the Treatment of COPD

COPD Clinical Trial

Official title:

A Multicenter, Randomized, Single-blind, Sham-controlled Clinical Trial to Evaluate the Safety and Effectiveness of Targeted Lung Denervation Radiofrequency Ablation Devices in the Treatment of Chronic Obstructive Pulmonary Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05799664
• Other study ID #: BC-TLD-02
• Status: Recruiting
• Phase: N/A
• Start date: July 4, 2023
• Est. completion date: August 2026

Study information

• Verified date: January 2024
• Source: Hangzhou Broncus Medical Co., Ltd.
• Contact: Liheng Xie
• Phone: +8613916444591
• Email: medicalaffairs[@]broncuschina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this trial is to evaluate the safety and effectiveness of Targeted Lung Denervation (TLD) for COPD patients using the lung denervation radiofrequency ablation device.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: August 2026
• Est. primary completion date: February 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Participants aged =40 and = 75 years;

2. Diagnosis of COPD with post-bronchodilator PFT parameters FEV1/FVC<70% and 20% = FEV1 = 60% of predicted; if FEV1<30%pred, PaCO2=50mmHg;

3. CAT = 10 or mMRC =2;

4. Non-smoking for a minimum of 2 months prior to consent and agrees to not smoke for the duration of the clinical investigation;

5. Recent participation in a formal pulmonary rehabilitation program should have occurred =3 months prior to consent; if participants are currently enrolled in a maintenance program, they should agree to continue their current program through their 12-month follow-up visit;

6. Documented history of taking standard medication (consistent with GOLD guideline<2022>) for =12 months at the time of consent;

7. Received an influenza vaccine within the 12 months prior to consent or agrees to obtain an influenza vaccine during the clinical investigation, and agrees to annual influenza vaccines for the duration of the clinical investigation;

8. Resting SpO2 = 89% at the time of screening;

9. Willing, able, and agrees to complete all protocol required baseline and follow-up testing assessments including finishing the Patient Diary;

10. Able to understand the purpose of the clinical investigation, agree to participate in the trial and able to complete the informed consent signature.

Exclusion Criteria:

1. BMI < 18 or > 35;

2. Asthma as defined by the GINA guideline (2022);

3. Patient has been previously diagnosed with a non-COPD active lung disease (e.g., active tuberculosis);

4. Patient has a medical history of pneumothorax;

5. Known contraindication or allergy to medications required for bronchoscopy or general anesthesia that cannot be medically controlled;

6. Recent respiratory infections or COPD exacerbation in preceding 4 weeks;

7. Malignancy treated with radiation or chemotherapy within 2 years of consent;

8. Daily use of > 10 mg of prednisone or its equivalent at the time of consent;

9. Recent (within 3 months of consent) opioid use;

10. Known gastrointestinal motility disorder or previous abdominal surgical procedure on stomach, esophagus, or pancreas

11. Has an implantable electronic device;

12. Previous or planned pulmonary or thoracic surgery (including but not limited to:

pneumonectomy, lung transplantation, pulmonary medical device intervention < e.g. pulmonary valve implantation, bronchial thermal ablation (BT), etc. >) during this trial;

13. Myocardial infarction within last 6 months, EKG with evidence of life-threatening arrhythmias or acute ischemia, pre-existing documented evidence of a LVEF < 45%, stage C or D (ACC/AHA) or Class III or IV (NYHA) congestive heart failure, or any other cardiac findings that make the participant an unacceptable candidate for a bronchoscopic procedure utilizing general anesthesia;

14. High risk of pulmonary hypertension according to clinical assessment, defined as pulmonary artery systolic pressure estimated by echocardiogram to be > 50 mmHg;

15. Pulmonary nodule or other lesions thought to be at high risk of malignancy;

16. Clinically relevant bronchiectasis, defined as severe single lobe or multilobar bronchial wall thickening associated with airway dilation on CT scan leading to cough, intractable expectoration and repeated hemoptysis lasting for several days;

17. In the opinion of the Investigator, use of the TLD devices is not feasible, for example, due to screening chest CT scan reveals severe emphysema or bronchi anatomy cannot be fully treated with available catheter sizes: severe bullous disease (> 1/3 hemithorax) or site discovery of a mass that requires treatment;

18. A GCSI total symptom score = 18.0 prior to treatment;

19. Any disease or condition that might interfere with completion of a procedure or this study (e.g., life expectancy< 1 years);

20. Women of childbearing potential must have a negative pregnancy test (blood or urine) pre-treatment and agree not to become pregnant for the duration of the study

21. Participated in any clinical trial and received experimental treatment within 3 months before the screening visit.

Related Conditions & MeSH terms

• COPD

Intervention

Device:
• TLD
Patients allocated to experimental group will receive TLD therapy during which radiofrequency energy will be delivered to vagus nerve surrounding airway under bronchoscopy.

Other:
• Sham TLD procedure
Patients allocated to control group will receive sham TLD procedure during which catheter will be placed in all treatment locations with no radiofrequency energy delivered.
• Standard of care
Patients will also receive standard of care that meet the recommendations of GOLD guideline.

Locations

Country	Name	City	State
China	West China Hospital of Sichuan University	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
Hangzhou Broncus Medical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of Forced expiratory volume in first second (FEV1) relative to baseline	Defined as change in FEV1 at 6 months relative to baseline in the experimental group, compared to the control group.	6 Months
Secondary	Time to first moderate or severe COPD exacerbation, first severe COPD exacerbation and first respiratory-related hospitalization.	Defined as a comparison between study arms of the survival distributions for events based on log-rank tests.	12 Months
Secondary	Change in St. George's Respiratory Questionnaire COPD Version (SGRQ-C) Total score	Defined as a comparison between study arms of the mean change in SGRQ-C from baseline.; The SGRQ-C is a questionnaire developed to measure health status (quality of life) in COPD patients with a total and three component scores for: symptoms, activity and impacts; each score ranges from 0 (no impairment) to 100 (worst possible).	6 and 12 Months
Secondary	Change in modified Medical Research Council (mMRC) scale Total score	Defined as a comparison between study arms of the mean change in mMRC from baseline.; The modified Medical Research Council (mMRC) scale is recommended for conducting assessments of dyspnea and disability and functions. Total score ranging 0 to 4. The higher the score, the more deterioration in severity of dyspnea.	6 and 12 Months
Secondary	Change in COPD Assessment Test (CAT) Total score	Defined as a comparison between study arms of the mean change in CAT from baseline.; The CAT is a disease-specific HRQL with eight questions; each score ranges from 0 (no impairment) to 5 (worst possible). The CAT has a scoring range of 0-40. Higher scores denote a more severe impact of COPD on a patient's life.	6 and 12 Months
Secondary	Change in Pulmonary Function	Defined as a comparison between study arms of the mean change in FEV1%pred, FVC(%pred), RV(%pred) from baseline.	6 and 12 Months
Secondary	Change in 6-minute walk distance (6MWD)	Defined as a comparison between study arms of the mean change in 6MWD from baseline.	6 and 12 Months
Secondary	Device Success Rate of experimental group	Defined as the proportion of the number of ablation procedures in which the catheter would be successfully placed on the treatment site and the catheter would be successfully withdrawn after the completion of the treatment procedure in all the ablation procedures.	Immediately after the procedure
Secondary	(Serious) Adverse Event Rate related to device or procedure	Defined as the total number of events per total number of treatment years.	Through study completion, an average of 1 year